🧬 在 CDK4/6 抑制剂治疗期间发生进展，并不一定意味着该通路的作用已被穷尽。
@OncoAlert
在 #ESMO26 上，postMONARCH 的最终 OS 分析评估了 abemaciclib + fulvestrant，用于既往接受 CDK4/6i + 内分泌治疗后出现进展的 HR+/HER2– 晚期 #BreastCancer 患者。
📊 n=368
➡️ 中位 OS：32.1 vs 24.6 个月
HR 0.80 (0.60–1.06)，p=0.1145
➡️ 更新后的 PFS：HR 0.78 (0.62–0.99)
➡️ 未发现新的安全性信号
OS 差异在数值上有意义，但未达到统计学显著性。
🎯 重要性在于：进展后继续抑制 CDK4/6 通路仍可能具有价值——但并非适用于每位患者，收益幅度也不会相同。
对我来说，真正的下一步是明确哪些患者在进展后仍在生物学上依赖 CDK，以及哪些患者应转而采用其他治疗通路。
这正是 postMONARCH 背后的精准医疗问题。
@KalinskyKevin、@BianchiniGP、@ErikaHamilton9、@DrSGraff、@drsarahsam、@MuozMateu 及研究团队完成了出色的工作。
艾特一下 @matteolambe、@aftimosp、@E_de_Azambuja、@hoperugo、@stolaney1、@kevinpunie、@ElisaAgostinett、@GaiaGriguolo、@JankovicK、@LoiSher
#OncoAlert #ESMO26 #BreastCancer #CDK46 #EndocrineTherapy #PrecisionOncology
247 浏览 · 3 赞 · 3 转发 · 0 回复
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 1RO: Final Overall Survival Analysis of postMONARCH: Abemaciclib Plus Fulvestrant After Progression on Prior CDK4/6 Inhibitor in HR+, HER2– Advanced Breast Cancer @KalinskyKevin @BianchiniGP @ErikaHamilton9 @DrSGraff @drsarahsam @MuozMateu 🔬 Phase 3, double-blind trial (n=368): abemaciclib or placebo plus fulvestrant in HR+, HER2– ABC after progression on prior CDK4/6i + ET. Final OS analysis. ➡️ Median OS 32.1 vs 24.6 mo; HR 0.80 (0.60–1.06); p=0.1145, statistical significance not reached ➡️ Updated PFS HR 0.78 (0.62–0.99); nominal p=0.0390 ➡️ Safety consistent with the established abemaciclib profile; no new signals ✅ Numerically longer median OS, not statistically significant. While absolute PFS benefit was modest, overall evidence supports considering abemaciclib-based treatment after disease progression on prior CDK4/6i + ET. #BreastCancer 🎙️ Kevin Kalinsky 👥 Giampaolo Bianchini · Erika Hamilton · Stephanie Graff · Kyong Hwa Park · Rinath Jeselsohn · Umut Demirci · Miguel Martin · Rachel Layman · Sara Hurvitz · Sarah Sammons · Peter Kaufman · Montserrat Muñoz · Jiun-I Lai · Holly Knoderer · Cynthia Sandoval · Aarti Chawla · Bastien Nguyen · Yanhong Zhou · Elizabeth Ravenberg · Lacey Litchfield · Lillian Smyth · Seth Wander (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista在 X 查看被引用的帖子
来源：Dra. María Natalia Gandur Quiroga · x.com